Medical Devices

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

Retrieved on: 
Saturday, April 6, 2024
Research, Technology, Medical Devices, Health Technology, Cardiology, Software, Health, Data Management, Science, Artificial Intelligence, Aortic stenosis, Aortic regurgitation, Patient, Mortality, MD, American College, TAVR, Multimedia, Teaching

egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).

Key Points: 
  • egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).
  • This press release features multimedia.
  • “This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor distinct characteristics in this population.
  • Recent conservative estimates suggest that over 500,000 patients in the United States are diagnosed with moderate or severe AR, indicating a substantial opportunity for novel therapeutic options to treat patients suffering from AR.

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Other Consumer, Medical Devices, Surgery, Women, LGBTQ+, Men, Consumer, Health, Cosmetics, Retail, Migraine, Type, Medical tourism, Elective surgery, COVID-19, Bariatric surgery, Hospital, Dermatology, IPL, Ageing, Breast, Cellulite, Safety, Market, Physician, FACE, Practitioner

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points: 
  • The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
  • Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
  • Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
  • North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.

Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

Retrieved on: 
Friday, April 5, 2024
Medical Devices, Health, Clinical Trials, Radiology, Cardiology, Biotechnology, Science, FIM, Patient, Journal, Research, Quality of life, American College, Calendar

Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.

Key Points: 
  • Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
  • This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.
  • Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.
  • Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT
    The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023:

PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors

Retrieved on: 
Friday, April 5, 2024
Oncology, Medical Devices, Health, Surgery, Clinical Trials, Biotechnology, Boston University, Toxicity, Hematology, Genetics, Executive, Monoclonal antibody, Shire (pharmaceutical company), Merck, Acquisition, BMS, Cancer, University, Doctor of Philosophy, Panther, MBA, Marketing, Neoplasm, Therapy, Chemical engineering, Genetics Institute, F-star, FDA, Pharmaceutical industry

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.

Key Points: 
  • PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
  • “John has been an outstanding addition to our Board and management team since joining the company in September.
  • His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
  • During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Italy Automated Microbiology Market Report 2023-2028 - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Medical Devices, Blood culture, Emerging technologies, Assay, SWOT analysis, Microbiology, Retail

The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.
  • This report is an analysis of the major business opportunities emerging in the automated microbiology market during the next five years.
  • The report examines key trends in the Italian automated microbiology market; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
Friday, April 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.

Sebia Receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Retrieved on: 
Friday, April 5, 2024
Other Health, General Health, Oncology, Biometrics, Technology, Medical Devices, Health Technology, Security, Online Privacy, Biotechnology, FDA, Other Technology, Health, Laboratory, Blood, Paper, DBS, DSM-IV codes, Food

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CAPILLARYS 3 DBS devices.

Key Points: 
  • Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CAPILLARYS 3 DBS devices.
  • This qualitative analysis is performed by capillary electrophoresis with the CAPILLARYS 3 DBS automated instrument.
  • This offer provides laboratories a gain in operational efficiency with high throughput and a full traceability from DBS card up to the result through a cyber-secured environment.
  • This will help laboratories to make timely and accurate decisions for newborns” said Arnaud Collin, Sebia Group Vice President Global Regulatory Affairs & Quality.